Adalimumab is a recombinant human IgG1κ monoclonal antibody which binds specifically to TNFα, thereby blocking interaction of TNFα with the p55 and p75 surface TNF receptors. Adalimumab binds to both soluble and cell-surface bound forms of TNFα.
TNFα is a central mediator of inflammation and is known to be dysregulated in a range of autoimmune diseases. TNFα blockers are thought to provide effective immunosuppression through a variety of mechanisms: neutralization of soluble and/or membrane-bound TNFα, direct cellular toxicity via complement-mediated lysis and/or antibody-dependent cytotoxicity, and induction of apoptosis or other downregulatory effects.
Adalimumab was first licensed for use in rheumatoid arthritis in 2001, and most recently was approved for use in juvenile idiopathic arthritis. Additional indications for adalimumab include Crohn's disease, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
rheumatoid arthritis
juvenile idiopathic arthritis
psoriatic arthritis
ankylosing spondylitis
Crohn's disease
plaque psoriasis
| Source | Link | Revision Date | Access Date |
| Humira Prescribing Information | http://www.humirapro.com/ | 2008-February | 2008-June-05 |
| Wong M, Ziring D, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008 Feb;126(2):121-36 | http://www.pubmedcentral.nih.gov/art...medid=17916444 | 2008-June-05 | |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2011 Clinical Immunology Society | Web Site Disclaimer |
